क्यूआर कोड

First-in-human, phase 1 study of CM512, a TSLP/IL-13 bispecific antibody, in healthy volunteers: safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity

PurposeType 2 chronic inflammatory diseases (e.g., atopic dermatitis and allergic rhinitis) impose a substantial global burden with unmet medical needs. Thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13) are key pathogenic drivers, and bispecific antibodies targeting both cytokines may o...

पूर्ण विवरण

में बचाया:
मुख्य लेखकों: Yue Cheng, Qingfeng Liu, Mengmeng Li, Yao Xie, Yuchun Men, Miao He, Huifang Wang, Xiwei Feng, Ming Zeng, Libo Zhang, Bo Chen, Jingyi Li, Ping Feng
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Frontiers Media S.A. 2026-05-01
श्रृंखला:Frontiers in Immunology
विषय:
CM512
immunogenicity
pharmacodynamics
pharmacokinetics
phase 1 study
safety
ऑनलाइन पहुंच:https://www.frontiersin.org/articles/10.3389/fimmu.2026.1811041/full
टैग: टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन